Objective An oral lactococcal-based vaccine which haboured the haemagglutinin1 (HA1) antigen fused to nisP anchor protein for the purpose of surface displaying the HA1 antigen was developed against H1N1 virus. Results Recombinant L. lactis strains expressed HA1-nisP fusion proteins when induced with nisin, as confirmed through western blotting. However, immunofluorescense did not detect any surface-displayed proteins, suggesting that the protein was either unsuccessfully translocated or improperly displayed. Despite this, oral administration of recombinant L. lactis strains to BALB/c mice revealed that significant levels of anti-HA1 sIgA antibodies were detected in mice fecal suspension samples of mice group NZ9000 (pNZ:HN) when compared to the negative control NZ9000 (pNZ8048) group. Conclusion Specific anti-HA1 sIgA antibodies were locally produced and live recombinant lactococcal vaccine was able to elicit humoral response of BALB/ c mice despite unsuccessful surface display of the HA1 epitope.
Introduction
An outbreak of a new influenza A (H1N1) viral strain emerged in Mexico in 2009, causing concern worldwide. A mortality rate of 39 % was reported (Perez-Padilla et al. 2009 ). Current available influenza vaccines are live attenuated viruses that are propagated in embryonated chicken eggs (Neumann et al. 2009 ). While this is effective in terms of providing immunogenic protection, there are several limitations and disadvantages of this method such as allergic reactions to egg proteins, biosafety issues and limited production capacity. The use of live bacterial vaccines eliminates the disadvantages of parentally administered vaccines as it (i) stimulates mucosal immune response by mimicking the entry route of many pathogens, (ii) can be administered orally or nasally without the need of professional healthcare infrastructure and prevents the risk associated with contaminated needles, and (iii) has simple downstream processing (Detmer and Glenting 2006) .
Lactococcus lactis has a long history of safe use in food fermentation, hence its Generally Regarded as Safe (GRAS) status. L. lactis is able to survive passage through the gastrointestinal tract of humans and animals, does not invade or colonize the mucosal surfaces of the host with a retention time of 2 to 3 days, and does not elicit a strong immune response in the host (Pozzi and Wells 1997; Savage 1977; Tannock 1999) , thereby making it a suitable candidate for an oral vaccine delivery system. In addition to its GRAS status, some Lactic Acid Bacteria are able to stimulate the immune system of the hosts as adjuvants due to their probiotic properties and immunomodulation capacity (Seegers 2002) .
One of the earlier attempts in using L. lactis as a live vector and vaccine candidate was oral immunization of mice with recombinant L. lactis producing tetanus toxin Fragment C (TTFC) and a secreted form of interleukin-12 (IL-12). Mice immunized with the recombinant L. lactis producing TTFC constitutively elicited systemic anti-TTFC immune responses and TTFC-specific fecal IgA responses could be detected following oral or intranasal immunization (Robinson et al. 1997) . Nevertheless, the most promising results were observed in L. lactis expressing cell wall anchored E7 which is a main candidate antigen for vaccines against HPV cervical cancer (Bermúdez- Humarán et al. 2005) .
Surface display of antigens on bacterial cell walls is commonly employed to allow direct interaction of the antigens with the immune system. There are several modes of anchoring proteins to lactic acid bacteria with LPXTG anchor motif being the most commonly used (Leenhouts et al. 1999) . While the LPXTG motif of the PrtP protein is frequently used, in this study we analysed the ability of the LPXTG motif of another protein, NisP (nisP-anc), to surface display the HA1 viral epitope on the cell wall of L. lactis. NisP is a serine protease required for the removal of the nisin signal peptide; nisin is a lantabiotic produced by certain strains of L. lactis. In addition, NisP is located extracellularly in L. lactis (Siezen et al. 1995) thereby making the anchor of NisP a potential candidate to surface display heterologous proteins. Therefore, in the current study, the HA1 epitope was fused to the NisP anchor and cloned into L. lactis with the aim of using L. lactis as a factory and vehicle for the production and delivery of the pandemic H1N1 2009 influenza viral vaccine.
Methods

Bacterial isolates and plasmids
Lactococcus lactis ATCC11454 genomic DNA was used as the template to amplify the nisP-anc and L. lactis NZ9000 was used as the host for the expression vector pNZ8048. All recombinant L. lactis strains produced in this study were transformed with vectors constructed using pNZ8048 as the backbone plasmid (Table 1) . Lactococcal cultures were grown as static cultures at 30°C in M17 media (Merck, Germany) supplemented with 0.5 % (w/v) glucose. When necessary, chloramphenicol was added to the culture media at 7.5 lg/ml.
PCR and conditions
The nisP-anc was PCR amplified from the genomic DNA extraction of L. lactis ATCC 11454 while the HA1 viral epitope was PCR amplified from E. coli pTriEx_HA1/L/AcmA plasmid. The primers used for the amplification are listed in Supplementary Table 1. PCR reaction was set up as following: Initial denaturation at 94°C for 2 min, 20 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 1 min and extension at 68°C for 2 min and final extension at 68°C for 7 min. PCR products were analysed with 1 % (w/v) agarose gel electrophoresis.
Cloning of pNZ:UHN, pNZ:HN and pNZ:H The HA1 viral epitope and nisP-anc was amplified and restriction sites were incorporated into the forward and reverse primers. In the construction of pNZ:UHN, HA1 was first fused to USP45 signal peptide using splicing overextension PCR. The HA1 viral epitope and nisP-anc was fused together with restriction enzyme EcoRI before cloning into pNZ8048 at the PstI/XbaI sites. The plasmid pNZ:HN was similarly constructed except without fusion to USP45 while pNZ:H was constructed by insertion of HA1 alone into pNZ8048. Electroporation was used for transforming the recombinant plasmid into NZ9000 competent cells (Holo and Nes 1995) . The transformed L. lactis recombinants were screened based on chloramphenicol resistance selection. Positive transformants were confirmed by colony PCR, restriction enzymes double digestion and sequencing.
Expression of L. lactis harbouring recombinant constructs
A single colony of L. lactis harbouring recombinant constructs were grown in GM17 broth supplemented with chloramphenicol at 30°C overnight. The overnight culture was transferred to fresh GM17 broth containing chloramphenicol until it reached OD 600 of 0.3-0.4. The culture was induced with 10 ng nisin/ml and was allowed to grow for 2 h at 30°C.
Protein extraction and western blotting
Nisin induced bacterial cells were harvested and centrifuged at 35009g for 10 min. The cell pellet was rinsed twice and resuspended in PBS. The suspension was disrupted on ice using ultrasound. Crude extracts were centrifuged at 10,0009g for 10 min at 4°C. The supernatant was collected and an equal volume of sample buffer [0.125 M Tris/HCl, pH 7.4, 4 % (w/v) SDS, 0.2 M DTT, 0.02 % (w/v) Bromophenol Blue and 20 % (v/v) glycerol] was added. The mixture was boiled at 95°C and used in SDS-PAGE or stored at -20°C. Western blotting was conducted by transferring separated proteins onto Immobilon PVDF membrane (Amresco, USA) using a semi-dry electroblotter. Dilution buffer with Tween 20 (DBT, -1.2 g dilution buffer powder in 100 ll Tween 20) from the chromogenic Western MAX horseradish peroxidase (HRP) kit (Amresco, USA) was prepared and the membrane was blocked with 5 % (w/v) skimmed milk dissolved in DBT at room temperature with gentle agitation on a platform shaker. After blocking, the membrane was incubated with 1 ll rabbit polyclonal anti-H1N1 primary antibodies (1 mg/ml) (Novus Biologicals, USA) diluted in 10 ml DBT with gentle agitation at RT. The membrane was then washed three times with DBT and was incubated with secondary antibody [anti rabbit (Calbiochem, USA)] conjugated with HRP at room temperature with gentle agitation. The membrane was washed thee times with DBT and the membrane was developed in the dark after the addition of 3,3 0 -diaminobenzidine (DAB).
In vivo immunogenicity studies An animal trial was conducted by orally administering L. lactis recombinant constructs to 6-8 weeks old female BALB/c mice. Each group contained six mice and prior to oral immunization, mice sera (100 ll) was collected through tail bleeding and fecal suspension obtained from fresh mice faeces. Oral immunization was performed simultaneously for all mice groups over 3 days, and three booster doses were administered every 2 weeks each with lactococcal culture normalized to OD 600 = 1 (*10 10 cells). Mice sera were taken through tail bleeding every week for prime immunization. Two weeks after the third booster, all mice were anesthetized using ketamine and xylazine prior to blood withdrawal through heart puncture which was performed with a 25G needle and syringe. The gut (esophagus until stomach) of each mice was carefully removed, soaked in 500 ml of sterile PBS and stored at 4°C. Stomach wash suspension was obtained by flushing the gut starting from the esophagus down with the spent PBS that the gut was soaked with. All in vivo experiments were approved by the Institutional Animal Care and Use Committee Sandwich ELISA 96-well ELISA plates were pre-coated with 50 ll 1 lg polyclonal anti-H1N1 antibody/ml (Novus Biologicals, USA), and incubated overnight at 4°C. After incubation, plates were washed five times with 200 ll PBS. Blocking was done with 200 ll blocking buffer [1 % (w/v) BSA in PBS], and incubated for 30 min at 37°C. After washing five times 50 ll purified HA1 protein (5 lg/ml) was added followed by incubation for 1 h at 37°C. Washing for five times was repeated and 50 ll pooled mice serum from each group diluted to 1:100 in PBS was added to each well. Plates were incubated for 1 h at 37°C, followed by washing five times before 50 ll HRP-conjugated anti-mouse antibodies (Calbiochem, USA) diluted in blocking buffer was added. The plate was incubated for 1 h at 37°C followed by washing for five times. 50 ll TMB Blue ELISA substrate (Sigma) was added to each well and the plate was incubated in dark at room temperature for 20 min. The reaction was stopped by the addition of 50 ll stopping solution (1 M H 2 SO 4 ) and the plate was immediately read with an ELISA plate reader at 450 nm.
Results and discussion
Construction of pNZ:UHN, pNZ:HN and pNZ:H
A fusion of usp45, HA1 viral epitope and nisP-anc was cloned into pNZ8048 plasmid where usp45 and nisPanc was fused to the N-and C-terminal of HA1, respectively. This resulted in pNZ:UHN which was later analysed for its potential application as a vaccine. Usp45 is an efficient lactococcal signal peptide used for targeting HA1 viral epitopes extracellularly. The plasmid pNZ:HN which lacked the USP45 signal peptide was also constructed for intracellular comparison in the animal trial. Additionally, pNZ:H, was constructed to produce HA1 viral epitopes for HA1 protein purification which was then employed during post-in vivo sandwich ELISA assays.
The expected protein size of the HA1 epitope alone and HA1-nisP fusion protein are *37 and *53 kDa, respectively. Figure 1 shows the western blot of intracellular proteins obtained from the L. lactis recombinant clones. Clear bands were observed at *35 kDa for the induced pNZ:H while no bands were observed in the pNZ8048 sample (negative control). Surprisingly, pNZ:UHN and pNZ:HN yielded two distinct bands corresponding to the size of HA1-nisP at *53 kDa which was the expected band and an additional *35 kDa band corresponding to the size of HA1 alone, presumably due to a breakage at the nisP anchor for unknown reasons. Due to this discrepancy, the bands were sent for MALDI-TOF analysis and were confirmed to be the HA1 viral epitope (data not shown). The recombinant NZ9000 (pNZ:UHN) strain was then analyzed for surface display of the HA1 epitope using immunofluorescence assay but results were negative (data not shown). Western blot results on the extracellular fraction of NZ9000 (pNZ:UHN) were also negative after 4 h post-induction (data not shown), demonstrating that not only did the nisP anchor failed to anchor the HA1 epitope to the cell wall, but translocation of HA1 out of the cells were also unsuccessful for unknown reasons.
While there have been many reports on highly successful and efficient secretion by Usp45, the signal peptide is not failure-proof as some research have reported unsuccessful secretion of heterologous proteins using Usp45, possibly owing to the nature of the heterologous proteins itself (Dieye et al. 2003 , Hazebrouck et al. 2007 ). In part, this problem can be solved by fusion with a pro-peptide or a carrier protein such as staphylococcal nuclease (Nuc) (Hazebrouck et al. 2007 ). Alternatively, secretion could take longer than 4 h post-induction which was the time extracellular expression was analysed by western blot in the present study. While secretion in L. lactis using Usp45 typically takes 1-3 h, there have been reports of secretion of heterologous protein taking 6-12 h to occur (Subramaniam et al. 2012 ). The only other study which attempted to use NisP anchor domain to surface display a cellulose-binding domain (CBD) also failed to anchor the CBD, although in this case, most of the CBD-NisP protein was found in the extracellular fraction in the degraded form (Liu et al. 2011 ). In the referred study, the CBD-NisP fusion was successfully translocated by Usp45 but NisP failed to anchor CBD to the cell wall, resulting in degraded CBD in the supernatant fraction owing to extracellular proteases activity.
Analysis of HA1-specific antibodies in mice sera by sandwich ELISA Since intracellular expression of antigens is also effective in eliciting a desirable immune response (Anuradha et al. 2010; Zamri et al. 2012) , NZ9000 (pNZ:UHN) and NZ9000 (pNZ:HN) cultures were administered orally to BALB/c mice, and their ability to elicit systemic and localized immune responses were analysed. Post-immunization samples (stomach wash, fecal suspensions and sera) obtained from different groups of immunized mice were analysed by sandwich ELISA assay. Although blood was sampled every week, only mice sera samples after the 3rd booster dose are shown in Fig. 2 since insignificant signal differences were obtained from prior mice sera samples in comparison to the sera of the PBS negative control group. Surprisingly, mice fecal suspension samples from the group fed with recombinant NZ9000 (pNZ:HN) showed the highest production of anti-HA sIgA antibodies (p \ 0.05) compared to the empty plasmid control NZ9000 (pNZ8048), even higher than NZ9000 (pNZ:UHN). Although pNZ:UHN also showed slightly elevated fecal anti-HA sigA antibodies, results were not significant compared to pNZ8048.
While the reason pNZ:HN was more immunogenic compared to pNZ:UHN was not investigated further, we postulate that the USP45 in pNZ:UHN would have enabled HA1 to be secreted eventually after more than 4 hours in the gut of the mice since we only performed Western blot on extracellular fractions up to 4 h which have yet to show secretion of HA1. Secretion of HA1 anchored to NisP anchor domain may have resulted in degradation of HA1, if following the example shown by the CBD-NisP protein in the study conducted by Liu et al. (2011) . This would explain why pNZ:HN which expressed HA1-NisP intracellularly could be more immunogenic compared to degraded Ha1-NisP secreted by pNZ:UHN. No significant signals were observed in stomach wash and sera samples compared to the PBS control when analysed with sandwich ELISA assay, suggesting the induction of localized mucosal immunity particularly along the intestinal lumen. Kimoto et al. (2003) studied the survival of lactococci during passage through the mouse digestive tract and reported that viable cells of L. lactis were recovered from mice feces within 24-48 h after administration but not after 72 h. The high signal observed in mice fecal suspension suggests that recombinant L. lactis cells survived passage through the upper gastrointestinal tract (oesophagus and stomach) of the mice, but subsequently ruptured as it approached the rectum. Due to intracellular expression of HA1, lactococcal cells may have to be lysed first before HA1 can be released for antigen presentation and to cause an effect. It is hypothesized that if HA1 was successfully anchored on the surface of the lactococcal cells as initially intended, there is a high probability that systemic immunity could be enhanced. Coincidentally, during the course of the current research, Lei et al. (2011) reported displayed HA1 (Lei et al. 2011 ) and neuraminidase (Lei et al. 2015) of H5N1 on the surface of L. lactis using type A1 pgsA anchor protein, in contrast to NisP, which is a type A3 anchor protein according to the system proposed by Leenhouts et al. (1999) . The oral vaccine increased serum IgG and mucosa IgA antibodies in BALB/c mice compared to controls; however, significant serum IgG and mucosa IgA antibodies were only elicited with co-administration of mucosal adjuvant cholerae toxin B (CTB).
Conclusion
A lactococcal vaccine elicited a significant mucosal response despite nisP-anc being unsuccessful in anchoring the HA1 epitope to the cell surface. Immunogenicity is anticipated to be enhanced if the antigen could be successfully displayed and administered together with an adjuvant. Fig. 2 Bar chart indicating ELISA signals obtained from mice stomach wash, fecal suspension and blood sera harvested at the end of in vivo immunogenicity studies. Highest signal observed was from mice fecal suspensions and the lowest signal was from mice stomach wash. From the fecal suspension analysis, significant anti-HA sIgA antibodies were produced (t test, p \ 0.05) in mice group NZ9000 (pNZ:HN) (asterisk) when compared to the empty plasmid control NZ9000 (pNZ8048). Data shown is an average of triplicates
